

Optogenetics in Epilepsy Research: Current Application and Future Directions

Alisha V. Xu

Milton Academy, 170 Center St, Milton, MA, 02186, USA; alishavxu@gmail.com

ABSTRACT: Optogenetics represents a transformative approach in neuroscience, enabling light-based control of genetically defined neuronal populations with unparalleled temporal and spatial precision. Within epilepsy research, this technology has opened new avenues for dissecting the mechanisms of seizure generation and developing highly targeted interventions. Epilepsy, a neurological disorder marked by recurrent seizures caused by abnormal neuronal synchronization, remains a major clinical challenge due to the limited specificity of existing treatments. By integrating microbial opsins, viral gene delivery systems, and advanced light delivery tools such as optical fibers and LEDs, researchers can modulate excitatory and inhibitory pathways in real time to restore network balance. Experimental applications across models of temporal lobe, neocortical, and post-stroke epilepsy demonstrate that selective activation or suppression of specific neurons can effectively halt or prevent seizure activity. This review synthesizes current advances in optogenetics and outlines its potential for future closed-loop therapeutic systems capable of detecting and interrupting seizures as they occur. We also discuss existing limitations, including limited light penetration, vector safety, and long-term stability, which currently restrict translation to human use. Despite these challenges, optogenetics remains a powerful platform in understanding and controlling epileptic circuits and a promising foundation for next-generation, personalized treatments for refractory epilepsy.

KEYWORDS: Medical and Health Sciences, Epilepsy, Optogenetics, Channelrhodopsin, Halorhodopsin.

■ Introduction

Epilepsy is one of the most prevalent neurological disorders; it is characterized by recurrent, unprovoked seizures resulting from abnormal synchronization of neuronal activity.¹ Globally, epilepsy affects approximately fifty million individuals and accounts for nearly 2.4 million new cases each year, with a disproportionate burden placed on developing countries where access to diagnosis and treatment may be limited.² These statistics emphasize the urgent need for more effective and accessible therapeutic strategies. Despite advances in pharmacological and surgical treatments, there is still an urgent need for more precise and effective interventions. Conventional antiepileptic drugs act by broadly suppressing neuronal excitability, often causing side effects such as cognitive impairment, fatigue, or mood disturbances; in addition, surgical resection can be risky when seizures originate in brain regions responsible for neurological functions such as language, movement, sensory processing, or memory.^{2,3} These limitations highlight a critical gap in therapeutic specificity and motivate the search for alternative strategies that can target dysfunctional neural circuits with high temporal and spatial precision. Optogenetics, a rapidly advancing technique that integrates genetic and optical methods to control neuronal activity with light, has emerged as a promising tool for both neuroscience research and potential clinical applications.⁴ By introducing light-sensitive opsins, such as *channelrhodopsins* (ChR2) and *halorhodopsins*, into specific neuron populations, optogenetics enables precise activation or inhibition of neural activity with millisecond precision.⁵ This approach offers a distinct advantage

over traditional electrical stimulation and pharmacological interventions, providing reversible and cell-type-specific modulation of brain circuits. In recent years, optogenetics has been successfully applied in experimental models of epilepsy to identify seizure-generating regions, suppress abnormal discharges, and restore network stability.⁶ However, its translation to human therapy remains limited by technical challenges, including restricted light penetration, viral delivery efficiency, and long-term biocompatibility.⁷ This review aims to provide an overview of optogenetic mechanisms, evaluate its advantages over conventional techniques, and examine its experimental applications in epilepsy research, with a focus on its therapeutic potential and current limitations.

■ Optogenetics

History of optogenetics:

Since the discovery of light-sensitive proteins in 1971 by Oesterhelt and Stoerkenius, the field of optogenetics has evolved into a complex technique that uses these proteins, various genetic delivery methods, and light delivery technologies.^{8,9} Specifically, optogenetics is a method that enables control of the activity of genetically modified cells using light. The term “optogenetics” was coined by Karl Deisseroth *et al.* in 2006.⁸ However, its foundational discoveries date back several decades. In 1971, Oesterhelt and Stoerkenius identified bacteriorhodopsin, a light-sensitive proton pump, located in *Halobacterium halobium*, a halophilic bacterium.⁹ This was the first known opsin capable of converting light into cellular activity. In the years that followed, many other microbial opsins were discovered,

including *halorhodopsin* in 1984,¹⁰ and ChR2 in 2002,¹¹ which would later become key components in optogenetic systems. In 2005, researchers successfully expressed ChR2 in mammalian neurons, demonstrating that light could directly trigger electrical activity in excitable cells.⁵ This study opens the door to precise manipulation of neural circuits, thereby advancing neuroscience research.

Various light-sensitive proteins:

The development and application of light-sensitive proteins known as “opsins,” which enable neuronal activation, are a crucial foundation of optogenetics. Among these, ChR2 is a light-gated cation channel originally discovered in green algae.¹² ChR2 can depolarize cells in response to specific wavelengths of light, making it an essential tool for neural excitation.¹³ Moreover, ChR2 is derived from *Chlamydomonas reinhardtii*, which responds to blue light. Initial experiments using ChR2 demonstrated that when expressed in the retinas of mice lacking functional photoreceptors, it could reintroduce light responsiveness by making the remaining neurons sensitive to light stimulation (Figure 1).¹⁴ However, despite its success, ChR2 has several drawbacks, including the need for high-intensity blue light and relatively slow response kinetics, which have driven the development of enhanced opsin variants with improved sensitivity and speed.¹⁵ In contrast to excitatory opsins like ChR2, optogenetics also utilizes inhibitory proteins to suppress neuronal activity. *Halorhodopsin* is a chloride pump that hyperpolarizes neurons by importing chloride ions in response to specific wavelengths of light, which reduces the likelihood of firing such neurons (Figure 1).^{16–19} Archaerhodopsins inhibit neuronal firing by pumping protons out of the cell.




Figure 1: Optical excitation and inhibition of neurons mediated by microbial opsins. Activation of channelrhodopsin channelrhodopsin-2 (ChR2) and *halorhodopsin*. ChR2 is activated by blue light (~470nm), opening a light light-gated cation channel, permitting the influx of positively charged ions such as Na⁺ and K⁺, resulting in membrane depolarization and increased neuronal firing. *Halorhodopsin* is activated by yellow light (590nm), driving chloride ions (Cl⁻) into the neuron, producing membrane hyperpolarization and suppression of action potential generation. Together, excitatory and inhibitory opsins enable wavelength-dependent, bidirectional control of neuronal activity, forming the mechanistic basis of optogenetic modulation of neural circuits (created in BioRender).

Genetic delivery methods:

In optogenetics, efficient gene-delivery techniques are essential for successful optogenetic applications; virus-mediated delivery and transgenic animal models are primary approaches for introducing light-sensitive proteins into target cells. Virus-mediated delivery utilizes viral vectors such as adeno-associated virus (AAV), lentivirus, and retrovirus.²⁰ These viral vectors have been genetically engineered to remove pathogenic components while retaining their capacity to insert transgenes into target cells.²⁰ These vectors efficiently transport genetic material across the cell membrane and into the nucleus without being degraded by lysosomes.²¹ While viral methods are more popular in clinical trials, comprising about 80% of all approved gene therapy protocols, they are not without limitations.²¹ For example, delivery to the central nervous system often requires invasive stereotactic injection, which carries risks including infection, hemorrhage, or tissue damage.²² Additionally, viral vectors may have limited spread within the brain, making it difficult to target large or anatomically complex epileptic networks, and immune responses against viral vectors remain a concern.²² As such, further research is needed to improve upon these challenges.

Light delivery technologies:

Light delivery technologies in optogenetics, primarily optical fibers and light-emitting diodes (LEDs), enable precise control of opsin activation in targeted tissues with minimal invasiveness. Optical fibers are commonly used in deep brain stimulation (DBS) because they can deliver high-intensity light with spatial precision to specific neural populations. Optical fibers are often surgically implanted to deliver light from external sources, such as lasers, directly to targeted brain regions, with careful consideration to minimize heat and light-induced tissue damage.²³ LEDs, on the other hand, provide a more compact and flexible alternative, especially useful for surface or shallow brain regions. LEDs can be integrated into head-mounted or implantable systems, allowing animals to move freely during experiments while still receiving targeted light stimulation.²³ Although optical fibers offer stronger light penetration and precise delivery, they can be more invasive and may disrupt tissue.²³ Recent advances in light delivery focus on improving precision and reducing tissue damage with techniques that offer selective targeting and high efficiency while maintaining cell viability, highlighting progress toward more targeted and less invasive methods.²⁴

Advantages of the optogenetics technique:

The advantages of optogenetics allow researchers to manipulate neuronal activity using temporal precision, bidirectional modulation, and cell-type specificity. Because optogenetics introduces light-sensitive opsins into targeted cells, precise control over specific neuron types can be achieved.⁵ The ability to restrict opsin expression to selected neuronal populations ensures that experimental manipulations affect only intended circuits, reducing the side effects and improving the reliability of results.²⁵ These opsins allow researchers to control the generation of action potentials, rapid electrical signals that

neurons use to communicate, with accuracy, providing the high temporal resolution essential for decoding neural activity patterns underlying behavior.⁵ This temporal precision allows scientists to deliver light pulses in precise sequences to generate specific firing patterns and then observe their effects, a process critical for understanding neural coding.⁵ Moreover, optogenetics offers bidirectional control, enabling both activation and inhibition of neural circuits; this control makes it more feasible to stimulate or suppress brain functions within the same network, even in complex regions such as the cortex.¹⁹ Thus, these features make optogenetics an advantageous tool for studying brain functions and developing treatments with minimized collateral damage.

■ Application of Optogenetics in Epilepsy

Applying optogenetics to temporal lobe epilepsy:

Temporal lobe epilepsy is characterized by focal seizure onset within mesial temporal structures, making it particularly amenable to spatially restricted interventions (Table 1).²⁶ Researchers utilized optogenetic techniques in a mouse model of temporal lobe epilepsy, demonstrating promising results in real-time seizure suppression through targeted intervention. Using a closed-loop detection system, researchers identified spontaneous seizures and responded immediately with light-based activation or inhibition of specific cell populations.²⁷ This strategy was motivated by the focal onset of temporal lobe seizures and the clinical need for seizure-abortive therapies that act precisely at seizure onset, particularly for patients who are not candidates for surgical resection or who are refractory to antiepileptic drugs.²⁷ The first strategy was to directly inhibit excitatory principal neurons using *halorhodopsin*, and the second was to activate GABAergic interneurons expressing ChR2. In this model, opsin expression was restricted to specific neuronal populations using Cre-dependent genetic approaches, ensuring cell-type specificity, while seizure detection relied on depth electrodes and real-time analysis of electrographic seizure signatures.²⁷ Upon seizure detection, light was delivered directly to the ipsilateral hippocampus, resulting in rapid suppression of ongoing seizures. Both approaches successfully stopped ongoing electrographic seizures upon light application, with significant reductions in behavioral seizure frequency as well.²⁷ Although both methods effectively suppressed seizures, they differed in mechanism, suggesting that multiple optogenetic strategies may be capable of restoring excitatory-inhibitory balance in epileptic circuits.²⁷ However, these studies remain limited because researchers were only able to target a small subset of hippocampal neurons, highlighting ongoing challenges in achieving widespread and precise neuronal targeting.²⁷ Despite these limitations, the integration of spontaneous seizure detection and optogenetic intervention in real time demonstrates significant future therapeutic potential.

Applying optogenetics to neocortical epilepsy:

Neocortical epilepsy represents a distinct focal epilepsy subtype in which seizures originate from lateral or extrahippocampal cortical regions and often require advanced diagnostic techniques for accurate localization (Table 1).²⁸ In a well-char-

acterized rodent model of neocortical epilepsy, focal injection of tetanus toxin, which interferes with inhibitory and excitatory signaling between neurons, into the motor cortex produces chronic, frequent seizures with high-frequency epileptiform EEG activity and contralateral motor signs that persist for months and are largely unresponsive to systemic diazepam or phenytoin.²⁹ Focal pharmacology at the seizure focus, however, can acutely suppress activity, as local application of NBQX, a highly selective competitive antagonist of AMPA, reversibly reduced both EEG and behavioral seizures without detectable side effects, underscoring the value of spatially targeted interventions.^{29,30} AMPA receptors are glutamate-gated ion channels crucial in rapid excitatory communication within the brain. Because epileptic seizures are associated with excessive excitatory signaling, selective blockade of these receptors using NBQX decreases neuronal overactivation and could limit seizures.³⁰ Building on this concept, continuous wireless EEG monitoring in the same tetanus toxin model revealed increased high-frequency activity and more frequent epileptiform events, along with heightened intrinsic excitability of pyramidal neurons at the epileptic focus, consistent with a local generator for seizures.³¹ Optogenetic inhibition of a subset of principal neurons was achieved through the delivery of *halorhodopsin* selectively restricted to the epileptogenic zone. Light-mediated suppression of these neurons significantly reduced electroencephalographic seizure activity *in vivo*, demonstrating that inhibiting a relatively small population of hyperexcitable cortical neurons is sufficient to disrupt seizure generation.³¹ These findings demonstrate how optogenetics may offer more targeted seizure control by selectively modulating pathological neural circuits while minimizing the effects on surrounding healthy tissue.^{29–31}

Applying optogenetics to post-stroke epilepsy:

Post-stroke epilepsy arises from structurally damaged cortex and associated networks, with seizure onset often occurring weeks to months after the initial injury (Table 1).³² It can be modeled by photothrombotic infarction, where large rose-bengal-induced cortical lesions extending to the cortical-subcortical interface lead to spontaneous seizures that emerge weeks after injury, with ictal discharges arising from peri-infarct cortex and characteristic motor arrest behaviors.³³ Longitudinal *in vivo* imaging of cortical pyramidal neurons demonstrates that excitatory activity in the peri-injury cortex is markedly reduced in the days immediately following stroke, as evidenced by decreased calcium spike frequency and fewer active neurons, before gradually recovering toward baseline levels, consistent with compensatory homeostatic regulation in surviving neurons.³⁴ Importantly, this transient loss of activity is associated with heightened seizure susceptibility, suggesting that insufficient excitatory drive may contribute to the development of post-stroke hyperexcitability. To test whether restoring activity could counteract this process, optogenetic stimulation was applied to selectively enhance pyramidal neuron activity in the peri-infarct cortex during the subacute post-stroke period. Targeted stimulation significantly reduced seizure susceptibility compared to unstimulated stroke con-

trols, indicating that optogenetic enhancement of cortical activity can prevent the emergence of severe seizures.³⁴ These findings suggest that post-stroke epilepsy may be prevented by timely optogenetic modulation that restores homeostatic balance within peri-infarct networks, highlighting activity enhancement as a novel and preventative therapeutic strategy rather than solely a reactive seizure-suppression approach.

Table 1: Clinical characteristics of focal epilepsy subtypes. Overview of major focal epilepsy subtypes discussed in this review, highlighting differences in seizure origin and clinical presentation.

Epilepsy Type	Primary Seizure Origin	Key Clinical Features
Temporal Lobe Epilepsy (TLE)	Mesial temporal structures (hippocampus, amygdala). ²⁶	Most common focal epilepsy; frequent auras and automatisms; often medically refractory. ²⁶
Neocortical Temporal Lobe Epilepsy (nTLE)	Lateral or extrahippocampal neocortex. ²⁸	Less common than mesial TLE; overlapping symptoms complicate localization. ^{28,31}
Post-Stroke Epilepsy (PSE)	Peri-infarct cortex and connected networks. ³²	Delayed seizure onset following stroke; high recurrence risk after late unprovoked seizures. ³²

■ **Therapeutic Implications and Future Directions (Limitations)**

Potential for clinical translation:

Optogenetics holds significant translational promise as a personalized therapy for epilepsy, offering targeted and reversible seizure control through closed-loop light delivery systems. A major vision for the future is a closed-loop implantable system that can detect abnormal brain activity in real-time and deliver light stimulation to suppress seizures before they spread, offering a more precise alternative to current responsive neurostimulation, which relies on electrical stimulation delivered to relatively broad neural populations, and can inadvertently modulate surrounding circuits, potentially limiting efficacy and contributing to off-target effects.^{7,35} Early studies in rodents have already demonstrated that implantable light-emitting devices can dynamically halt seizures, and encouraging progress has been made in nonhuman primates, where stable opsin expression has been paired with behavioral modulation and MRI-compatible optrodes.^{6,36,37} Computational modeling further supports the feasibility of scaling this approach to the human brain.³⁸ In the long term, optogenetics may even influence drug development by helping identify the neuronal subtypes most critical for seizure generation, thereby guiding new pharmacological strategies. Collectively, these directions highlight the promise of optogenetics as a foundation for future personalized therapies in epilepsy.⁷

Limitations and challenges:

While optogenetics shows immense promise as a therapeutic tool for epilepsy, significant technical, biological, and ethical challenges must be addressed before clinical translation is possible. On the technical side, the large size of the human brain compared to rodents makes it difficult for light to penetrate enough tissue to modulate an epileptic network effectively, and deeper brain foci may be inaccessible without

invasive procedures.^{7,39} Multiple viral injections may be required to reach sufficient neurons, and even then, the limited penetration of visible light risks heating and damaging nearby cells.⁴⁰ Device miniaturization poses another barrier: closed-loop systems would require long-lasting, rechargeable power sources and flexible, durable optrodes capable of maintaining stability in the brain for years.⁷ Biologically, uncertainties remain about the safety and stability of opsin expression over decades in humans, since current methods rely on viral vectors such as AAV or lentivirus; although stable expression has been observed in nonhuman primates for months,^{5,35} the long-term persistence and safety in humans remain unclear.^{41–43} Immunogenicity is also a concern, as opsins are non-mammalian proteins that could elicit antibody-associated immune responses.³⁹ Moreover, functional risks exist, including the possibility that prolonged activation of *halorhodopsin* could shift intracellular chloride gradients, thereby paradoxically rendering GABA signaling excitatory.⁴⁴ Finally, ethical and regulatory considerations pose significant barriers, as invasive brain procedures, such as viral delivery or stem cell transplantation, may face resistance from institutional review boards.⁷ Permanent optical implants raise further concerns about reversibility and patient safety. While comparisons have been made to accepted interventions, including deep brain stimulation (DBS) and vagus nerve stimulation (VNS), optogenetics introduces the added complexity of genetic modification, intensifying regulatory scrutiny.³⁵ Together, these limitations highlight the critical obstacles that must be overcome before optogenetics can move from experimental models to clinical practice.

■ **Conclusion**

Epilepsy, a chronic neurological disorder characterized by recurrent seizures arising from abnormal and excessive neuronal synchronization, remains a major clinical challenge due to the limited specificity of current treatment options.⁴⁵ Optogenetics has revolutionized the study and potential treatment of epilepsy by enabling precise, light-based modulation of specific neuronal populations. Through the integration of microbial opsins, viral delivery systems, and advanced illumination technologies, researchers have achieved unprecedented control over neural circuits, demonstrating that selective activation or inhibition of targeted neurons can suppress seizures in multiple experimental models.⁴ These findings show the promise of optogenetics as a therapeutic approach that could eventually surpass the specificity and adaptability of current interventions such as pharmacological treatments or deep brain stimulation. However, several limitations remain before clinical translation can be realized. Restricted light penetration, concerns about viral vector safety, immune responses, and the long-term stability of opsin expression all pose major challenges for human application.^{41–43} In comparison, while current epilepsy treatments such as antiepileptic drugs and surgical interventions may provide partial seizure control, they lack precision and can fail in drug-resistant cases.⁴⁶ This lack of security in current therapies highlights the need for more targeted approaches. Ethical considerations regarding the invasiveness of optical implants, patient autonomy, long-term invasiveness of implanted optical

devices, and genetic modification further complicate clinical implementation.⁴⁷ Consequently, researchers have also raised concerns regarding the need for stronger legal and regulatory frameworks before optogenetics can be safely translated into clinical practice.⁴⁷ Future research should focus on improving gene delivery methods to ensure stable, safe, and cell-type-specific expression. By addressing these obstacles, optogenetics may ultimately evolve from an experimental technique into a clinically viable therapy.

■ Acknowledgments

I would like to sincerely thank Dr. Daniel Kim, PhD, for his mentorship and guidance, and Indigo Research for their support in the publication process. I am also extremely grateful for the encouragement I have received from my parents.

■ References

- Shorvon, S. D. The Etiologic Classification of Epilepsy. *Epilepsia* **2011**, 52 (6), 1052–1057. <https://doi.org/10.1111/j.1528-1167.2011.03041.x>.
- Alam, S. M. S.; Bhuiyan, M. I. H. Detection of Seizure and Epilepsy Using Higher Order Statistics in the EMD Domain. *IEEE J. Biomed. Health Inform.* **2013**, 17 (2), 312–318. <https://doi.org/10.1109/JBHI.2012.2237409>.
- Paz, J. T.; Davidson, T. J.; Frechette, E. S.; Delord, B.; Parada, I.; Peng, K.; Deisseroth, K.; Huguenard, J. R. Closed-Loop Optogenetic Control of Thalamus as a Tool for Interrupting Seizures after Cortical Injury. *Nat. Neurosci.* **2013**, 16 (1), 64–70. <https://doi.org/10.1038/nn.3269>.
- Deisseroth, K. Optogenetics. *Nat. Methods* **2011**, 8 (1), 26–29. <https://doi.org/10.1038/nmeth.f.324>.
- Boyden, E. S.; Zhang, F.; Bamberg, E.; Nagel, G.; Deisseroth, K. Millisecond-Timescale, Genetically Targeted Optical Control of Neural Activity. *Nat. Neurosci.* **2005**, 8 (9), 1263–1268. <https://doi.org/10.1038/nn1525>.
- Diester, I.; Kaufman, M. T.; Mogri, M.; Pashaie, R.; Goo, W.; Yizhar, O.; Ramakrishnan, C.; Deisseroth, K.; Shenoy, K. V. An Optogenetic Toolbox Designed for Primates. *Nat. Neurosci.* **2011**, 14 (3), 387–397. <https://doi.org/10.1038/nn.2749>.
- Bui, A. D.; Alexander, A.; Soltesz, I. Seizing Control: From Current Treatments to Optogenetic Interventions in Epilepsy. *Neurosci. Rev. J. Bringing Neurobiol. Neurol. Psychiatry* **2017**, 23 (1), 68–81. <https://doi.org/10.1177/1073858415619600>.
- Deisseroth, K.; Feng, G.; Majewska, A. K.; Miesenböck, G.; Ting, A.; Schnitzer, M. J. Next-Generation Optical Technologies for Illuminating Genetically Targeted Brain Circuits. *J. Neurosci. Off. J. Soc. Neurosci.* **2006**, 26 (41), 10380–10386. <https://doi.org/10.1523/JNEUROSCI.3863-06.2006>.
- Oesterhelt, D.; Stoeckenius, W. Rhodopsin-like Protein from the Purple Membrane of Halobacterium Halobium. *Nature. New Biol.* **1971**, 233 (39), 149–152. <https://doi.org/10.1038/newbio233149a0>.
- Sugiyama, Y.; Mukohata, Y. Isolation and Characterization of Halorhodopsin from Halobacterium Halobium. *J. Biochem. (Tokyo)* **1984**, 96 (2), 413–420. <https://doi.org/10.1093/oxfordjournals.jbchem.a134852>.
- Nagel, G.; Ollig, D.; Fuhrmann, M.; Kateriya, S.; Musti, A. M.; Bamberg, E.; Hegemann, P. Channelrhodopsin-1: A Light-Gated Proton Channel in Green Algae. *Science* **2002**, 296 (5577), 2395–2398. <https://doi.org/10.1126/science.1072068>.
- Nagel, G.; Szellas, T.; Kateriya, S.; Adeishvili, N.; Hegemann, P.; Bamberg, E. Channelrhodopsins: Directly Light-Gated Cation Channels. *Biochem. Soc. Trans.* **2005**, 33 (Pt 4), 863–866. <https://doi.org/10.1042/BST0330863>.
- Deisseroth, K.; Hegemann, P. The Form and Function of Channelrhodopsin. *Science* **2017**, 357 (6356), eaan5544. <https://doi.org/10.1126/science.aan5544>.
- Bi, A.; Cui, J.; Ma, Y.-P.; Olshevskaya, E.; Pu, M.; Dizhoor, A. M.; Pan, Z.-H. Ectopic Expression of a Microbial-Type Rhodopsin Restores Visual Responses in Mice with Photoreceptor Degeneration. *Neuron* **2006**, 50 (1), 23–33. <https://doi.org/10.1016/j.neuron.2006.02.026>.
- Poboży, K.; Poboży, T.; Domański, P.; Derczyński, M.; Konarski, W.; Domańska-Poboża, J. Evolution of Light-Sensitive Proteins in Optogenetic Approaches for Vision Restoration: A Comprehensive Review. *Biomedicines* **2025**, 13 (2), 429. <https://doi.org/10.3390/biomedicines13020429>.
- Han, X.; Boyden, E. S. Multiple-Color Optical Activation, Silencing, and Desynchronization of Neural Activity, with Single-Spike Temporal Resolution. *PLoS One* **2007**, 2 (3), e299. <https://doi.org/10.1371/journal.pone.0000299>.
- Lima, S. Q.; Hromádka, T.; Znamenskiy, P.; Zador, A. M. PINP: A New Method of Tagging Neuronal Populations for Identification during *in Vivo* Electrophysiological Recording. *PLoS One* **2009**, 4 (7), e6099. <https://doi.org/10.1371/journal.pone.0006099>.
- Shimano, T.; Fyk-Kolodziej, B.; Mirza, N.; Asako, M.; Tomoda, K.; Bledsoe, S.; Pan, Z. H.; Molitor, S.; Holt, A. G. Assessment of the AAV-Mediated Expression of Channelrhodopsin-2 and Halorhodopsin in Brainstem Neurons Mediating Auditory Signaling. *Brain Res.* **2013**, 1511, 138–152. <https://doi.org/10.1016/j.brainres.2012.10.030>.
- Zhang, F.; Wang, L.-P.; Brauner, M.; Liewald, J. F.; Kay, K.; Watzke, N.; Wood, P. G.; Bamberg, E.; Nagel, G.; Gottschalk, A.; Deisseroth, K. Multimodal Fast Optical Interrogation of Neural Circuitry. *Nature* **2007**, 446 (7136), 633–639. <https://doi.org/10.1038/nature05744>.
- Kamimura, K.; Suda, T.; Zhang, G.; Liu, D. Advances in Gene Delivery Systems. *Pharm. Med.* **2011**, 25 (5), 293–306. <https://doi.org/10.2165/11594020-000000000-00000>.
- Wivel, N. A.; Wilson, J. M. Methods of Gene Delivery. *Hematol. Oncol. Clin. North Am.* **1998**, 12 (3), 483–501. [https://doi.org/10.1016/s0889-8588\(05\)70004-6](https://doi.org/10.1016/s0889-8588(05)70004-6).
- Shen, Y.; Campbell, R. E.; Côté, D. C.; Paquet, M.-E. Challenges for Therapeutic Applications of Opsin-Based Optogenetic Tools in Humans. *Front. Neural Circuits* **2020**, 14, 41. <https://doi.org/10.3389/fncir.2020.00041>.
- Emiliani, V.; Entcheva, E.; Hedrich, R.; Hegemann, P.; Konrad, K. R.; Lüscher, C.; Mahn, M.; Pan, Z.-H.; Sims, R. R.; Vierock, J.; Yizhar, O. Optogenetics for Light Control of Biological Systems. *Nat. Rev. Methods Primer* **2022**, 2, 55. <https://doi.org/10.1038/s43586-022-00136-4>.
- Mohanty, S. K.; Lakshminarayanan, V. Optical Techniques in Optogenetics. *J. Mod. Opt.* **2015**, 62 (12), 949–970. <https://doi.org/10.1080/09500340.2015.1010620>.
- Lin, J. Y.; Lin, M. Z.; Steinbach, P.; Tsien, R. Y. Characterization of Engineered Channelrhodopsin Variants with Improved Properties and Kinetics. *Biophys. J.* **2009**, 96 (5), 1803–1814. <https://doi.org/10.1016/j.bpj.2008.11.034>.
- Blair, R. D. G. Temporal Lobe Epilepsy Semiology. *Epilepsy Res. Treat.* **2012**, 2012, 751510. <https://doi.org/10.1155/2012/751510>.
- Krook-Magnuson, E.; Armstrong, C.; Oijala, M.; Soltesz, I. On-Demand Optogenetic Control of Spontaneous Seizures in

- Temporal Lobe Epilepsy. *Nat. Commun.* **2013**, *4*, 1376. <https://doi.org/10.1038/ncomms2376>.
28. Bercovici, E.; Kumar, B. S.; Mirsattari, S. M. Neocortical Temporal Lobe Epilepsy. *Epilepsy Res. Treat.* **2012**, *2012*, 103160. <https://doi.org/10.1155/2012/103160>.
 29. Nilsen, K. E.; Walker, M. C.; Cock, H. R. Characterization of the Tetanus Toxin Model of Refractory Focal Neocortical Epilepsy in the Rat. *Epilepsia* **2005**, *46* (2), 179–187. <https://doi.org/10.1111/j.0013-9580.2005.26004.x>.
 30. Libbey, J. E.; Hanak, T. J.; Doty, D. J.; Wilcox, K. S.; Fujinami, R. S. NBQX, a Highly Selective Competitive Antagonist of AMPA and KA Ionotropic Glutamate Receptors, Increases Seizures and Mortality Following Picornavirus Infection. *Exp. Neurol.* **2016**, *280*, 89–96. <https://doi.org/10.1016/j.expneurol.2016.04.010>.
 31. Wykes, R. C.; Heeroma, J. H.; Mantoan, L.; Zheng, K.; MacDonald, D. C.; Deisseroth, K.; Hashemi, K. S.; Walker, M. C.; Schorge, S.; Kullmann, D. M. Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical Epilepsy. *Sci. Transl. Med.* **2012**, *4* (161), 161ra152. <https://doi.org/10.1126/scitranslmed.3004190>.
 32. Tanaka, T.; Ihara, M. Post-Stroke Epilepsy. *Neurochem. Int.* **2017**, *107*, 219–228. <https://doi.org/10.1016/j.neuint.2017.02.002>.
 33. Kelly, K. M.; Kharlamov, A.; Hentosz, T. M.; Kharlamova, E. A.; Williamson, J. M.; Bertram, E. H.; Kapur, J.; Armstrong, D. M. Photothrombotic Brain Infarction Results in Seizure Activity in Aging Fischer 344 and Sprague Dawley Rats. *Epilepsy Res.* **2001**, *47* (3), 189–203. [https://doi.org/10.1016/s0920-1211\(01\)00294-7](https://doi.org/10.1016/s0920-1211(01)00294-7).
 34. Adhikari, Y.; Ma, C.-G.; Chai, Z.; Jin, X. Preventing Development of Post-Stroke Hyperexcitability by Optogenetic or Pharmacological Stimulation of Cortical Excitatory Activity. *Neurobiol. Dis.* **2023**, *184*, 106233. <https://doi.org/10.1016/j.nbd.2023.106233>.
 35. Tsytsarev, V.; Sopova, J. V.; Leonova, E. I.; Inyushin, M.; Markina, A. A.; Chirinskaite, A. V.; Volnova, A. B. Neurophonic Methods in Approach to *in Vivo* Animal Epileptic Models: Advantages and Limitations. *Epilepsia* **2024**, *65* (3), 600–614. <https://doi.org/10.1111/epi.17870>.
 36. Gerits, A.; Farivar, R.; Rosen, B. R.; Wald, L. L.; Boyden, E. S.; Vanduffel, W. Optogenetically Induced Behavioral and Functional Network Changes in Primates. *Curr. Biol. CB* **2012**, *22* (18), 1722–1726. <https://doi.org/10.1016/j.cub.2012.07.023>.
 37. Han, X.; Qian, X.; Bernstein, J. G.; Zhou, H.-H.; Franzesi, G. T.; Stern, P.; Bronson, R. T.; Graybiel, A. M.; Desimone, R.; Boyden, E. S. Millisecond-Timescale Optical Control of Neural Dynamics in the Nonhuman Primate Brain. *Neuron* **2009**, *62* (2), 191–198. <https://doi.org/10.1016/j.neuron.2009.03.011>.
 38. Selvaraj, P.; Sleight, J. W.; Freeman, W. J.; Kirsch, H. E.; Szeri, A. J. Open Loop Optogenetic Control of Simulated Cortical Epileptiform Activity. *J. Comput. Neurosci.* **2014**, *36* (3), 515–525. <https://doi.org/10.1007/s10827-013-0484-2>.
 39. Wykes, R. C.; Kullmann, D. M.; Pavlov, I.; Magloire, V. Optogenetic Approaches to Treat Epilepsy. *J. Neurosci. Methods* **2016**, *260*, 215–220. <https://doi.org/10.1016/j.jneumeth.2015.06.004>.
 40. Pavlov, I.; Kaila, K.; Kullmann, D. M.; Miles, R. Cortical Inhibition, pH and Cell Excitability in Epilepsy: What Are Optimal Targets for Antiepileptic Interventions? *J. Physiol.* **2013**, *591* (4), 765–774. <https://doi.org/10.1113/jphysiol.2012.237958>.
 41. Bartus, R. T.; Baumann, T. L.; Siffert, J.; Herzog, C. D.; Alterman, R.; Boulis, N.; Turner, D. A.; Stacy, M.; Lang, A. E.; Lozano, A. M.; Olanow, C. W. Safety/Feasibility of Targeting the Substantia Nigra with AAV2-Neurturin in Parkinson Patients. *Neurology* **2013**, *80* (18), 1698–1701. <https://doi.org/10.1212/WNL.0b013e3182904faa>.
 42. Fisher, R. S. Therapeutic Devices for Epilepsy. *Ann. Neurol.* **2012**, *71* (2), 157–168. <https://doi.org/10.1002/ana.22621>.
 43. Palfi, S.; Gurruchaga, J. M.; Ralph, G. S.; Lepetit, H.; Lavis, S.; Buttery, P. C.; Watts, C.; Miskin, J.; Kelleher, M.; Deeley, S.; Iwamuro, H.; Lefaucheur, J. P.; Thiriez, C.; Fenelon, G.; Lucas, C.; Brugières, P.; Gabriel, I.; Abhay, K.; Drouot, X.; Tani, N.; Kas, A.; Ghaleh, B.; Le Corvoisier, P.; Dolphin, P.; Breen, D. P.; Mason, S.; Guzman, N. V.; Mazarakis, N. D.; Radcliffe, P. A.; Harrop, R.; Kingsman, S. M.; Rascol, O.; Naylor, S.; Barker, R. A.; Hantraye, P.; Remy, P.; Cesaro, P.; Mitrophanous, K. A. Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinson's Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial. *Lancet Lond. Engl.* **2014**, *383* (9923), 1138–1146. [https://doi.org/10.1016/S0140-6736\(13\)61939-X](https://doi.org/10.1016/S0140-6736(13)61939-X).
 44. Raimondo, J. V.; Kay, L.; Ellender, T. J.; Akerman, C. J. Optogenetic Silencing Strategies Differ in Their Effects on Inhibitory Synaptic Transmission. *Nat. Neurosci.* **2012**, *15* (8), 1102–1104. <https://doi.org/10.1038/nn.3143>.
 45. Stafstrom, C. E.; Carmant, L. Seizures and Epilepsy: An Overview for Neuroscientists. *Cold Spring Harb. Perspect. Med.* **2015**, *5* (6), a022426. <https://doi.org/10.1101/cshperspect.a022426>.
 46. Berg, A. T.; Langfitt, J.; Shinnar, S.; Vickrey, B. G.; Sperling, M. R.; Walczak, T.; Bazil, C.; Pacia, S. V.; Spencer, S. S. How Long Does It Take for Partial Epilepsy to Become Intractable? *Neurology* **2003**, *60* (2), 186–190. <https://doi.org/10.1212/01.wnl.0000031792.89992.ec>.
 47. White, M.; Mackay, M.; Whittaker, R. Taking Optogenetics into the Human Brain: Opportunities and Challenges in Clinical Trial Design. *Open Access J. Clin. Trials* **2020**, *2020*, 33–41. <https://doi.org/10.2147/OAJCT.S259702>.

■ Authors

Alisha Xu is a junior at Milton Academy from Massachusetts. She has always shown a love for biology and wishes to continue this passion in the future through studying medicine. Alisha enjoys art, music, and playing various sports.